BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 26157328)

  • 1. Usefulness of human epididymis protein 4 in predicting cytoreductive surgical outcomes for advanced ovarian tubal and peritoneal carcinoma.
    Tang Z; Chang X; Ye X; Li Y; Cheng H; Cui H
    Chin J Cancer Res; 2015 Jun; 27(3):309-17. PubMed ID: 26157328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study.
    Feng LY; Liao SB; Li L
    J Ovarian Res; 2020 Feb; 13(1):17. PubMed ID: 32050995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
    Shen Y; Li L
    Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of human epididymis protein 4 in predicting optimal cytoreductive therapy in patients with advanced ovarian cancer.
    Paunovic V; Protrka Z; Ardalic D; Paunovic T
    J BUON; 2017; 22(1):29-33. PubMed ID: 28365932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative serum level of CA153 and a new model to predict the sub-optimal primary debulking surgery in patients with advanced epithelial ovarian cancer.
    Jia Y; Jiang Y; Fan X; Zhang Y; Li K; Wang H; Ning X; Yang X
    World J Surg Oncol; 2024 Feb; 22(1):64. PubMed ID: 38395933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human Epididymis Protein 4 (HE4) and Cancer Antigen 125 (CA125) for Prediction of Optimal Primary Surgery in Non-Mucinous Epithelial Ovarian Cancer.
    Promchit K; Oranratanaphan S
    Asian Pac J Cancer Prev; 2024 Jan; 25(1):281-286. PubMed ID: 38285795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of HE4, a Novel Biomarker, in Predicting Optimal Cytoreduction After Neoadjuvant Chemotherapy in Advanced Ovarian Cancer.
    Plotti F; Scaletta G; Capriglione S; Montera R; Luvero D; Lopez S; Gatti A; De Cicco Nardone C; Terranova C; Angioli R
    Int J Gynecol Cancer; 2017 May; 27(4):696-702. PubMed ID: 28406844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma?
    Angioli R; Plotti F; Capriglione S; Aloisi A; Montera R; Luvero D; Miranda A; Cafà EV; Damiani P; Benedetti-Panici P
    Gynecol Oncol; 2013 Mar; 128(3):579-83. PubMed ID: 23220563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of preoperative plasma tumor markers HE4 and CA125 in predicting ovarian cancer mortality in women with epithelial ovarian cancer.
    Furrer D; Grégoire J; Turcotte S; Plante M; Bachvarov D; Trudel D; Têtu B; Douville P; Bairati I
    PLoS One; 2019; 14(6):e0218621. PubMed ID: 31220149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis and preoperative predictive value of serum HE4 concentrations for optimal debulking in epithelial ovarian cancer.
    Yang Z; Luo Z; Zhao B; Zhang W; Zhang J; Li Z; Li L
    Oncol Lett; 2013 Jul; 6(1):28-34. PubMed ID: 23946773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minilaparotomy, Cyfra21-1, and Other Predicting Factors for Suboptimal Cytoreductive Surgery in Advanced Epithelial Ovarian Cancer: A Pilot Study.
    Nantasupha C; Pojchamarnwiputh S; Charoenkwan K
    Asian Pac J Cancer Prev; 2022 Dec; 23(12):4119-4124. PubMed ID: 36579993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer.
    Pelissier A; Roulot A; Guéry B; Bonneau C; Bellet D; Rouzier R
    J Ovarian Res; 2016 Sep; 9(1):61. PubMed ID: 27677313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revised Cut-Off Value of Human Epididymis Protein 4 Enhances Its Use as an Ovarian Tumor Marker.
    Machida H; Hirakawa T; Tsunekawa K; Kimura T; Murakami M; Abe Y
    Gynecol Obstet Invest; 2023; 88(6):349-358. PubMed ID: 37788640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of preoperative neutrophil-lymphocyte ratio and human epididymis protein 4 in predicting lymph node metastasis in endometrial cancer patients.
    Gao M; Gao Y
    J Obstet Gynaecol Res; 2021 Feb; 47(2):515-520. PubMed ID: 33142358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer.
    Chudecka-Głaz AM; Cymbaluk-Płoska AA; Menkiszak JL; Sompolska-Rzechuła AM; Tołoczko-Grabarek AI; Rzepka-Górska IA
    J Ovarian Res; 2014; 7():62. PubMed ID: 25018782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Model for Prediction of Optimal Debulking of Epithelial Ovarian Cancer.
    Arab M; Jamdar F; Sadat Hosseini M; Ghodssi- Ghasemabadi R; Farzaneh F; Ashrafganjoei T
    Asian Pac J Cancer Prev; 2018 May; 19(5):1319-1324. PubMed ID: 29802693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin.
    Stiekema A; Boldingh QJ; Korse CM; van der Noort V; Boot H; van Driel WJ; Kenter GG; Lok CA
    Gynecol Oncol; 2015 Mar; 136(3):562-6. PubMed ID: 25560808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative markers for the prediction of high-risk features in endometrial cancer.
    Panyavaranant P; Manchana T
    World J Clin Oncol; 2020 Jun; 11(6):378-388. PubMed ID: 32874951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
    Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
    Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer.
    Memarzadeh S; Lee SB; Berek JS; Farias-Eisner R
    Int J Gynecol Cancer; 2003; 13(2):120-4. PubMed ID: 12657110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.